Screener
BridgeBio Pharma BBIO Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Operating lease right-of-use assets | 17,226 | 8,149 |
| Intangible assets, net | 27,359 | 28,077 |
| Other assets | 18,620 | 16,712 |
| Total assets | $1,370,981 | $936,025 |
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $29,058 | $36,228 |
| Accrued compensation and benefits | 39,338 | 76,703 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's total assets?
- BridgeBio Pharma (BBIO) reported total assets of $1.37B in Q1 2026.
- How has BridgeBio Pharma's total assets changed year-over-year?
- BridgeBio Pharma's total assets increased by 55.5% year-over-year, from $881.64M to $1.37B.
- What is the long-term trend for BridgeBio Pharma's total assets?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total assets has grown at a 5.9% compound annual growth rate (CAGR), from $703.59M to $936.03M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about BridgeBio Pharma's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude